Conference-Safeguarding Adult/Pediatric Stem Cell Donors

描述（由申请人提供）： 该补助金是为了支持向NIH提交的R-13申请（会议和科学会议的补助金支持），用于非经常性的一天半会议，题为：保护成人和儿科干细胞捐献者：基础科学，临床和伦理问题。研讨会将于2004年9月21日星期二（上午和下午）和9月22日星期三（仅上午）在马里兰州贝塞斯达的Masur礼堂NIH临床中心（10号楼）举行。这个为期一天半的研讨会将旨在解决与儿童和成人，相关和无关的同种异体供体通过骨髓抽吸，外周血干细胞或脐带血采集提供干细胞的安全性相关的关键问题。这些问题的例子包括G-CSF动员的安全性和作用机制，骨髓抽吸引起的肌肉骨骼和神经肌肉损伤的风险，单采外周血干细胞供体中低钙血症和中心导管并发症的风险，以及将相关供体（特别是儿科供体）暴露于G-CSF或其他动员剂的伦理学。演讲者将包括成人和儿科干细胞移植领域的领导者，伦理学家和输血医学专家。研讨会的目的1将是促进国家或国际捐赠者登记数据库的发展，该数据库将在捐赠后数年内跟踪匹配的无关和相关的同种异体捐赠者。该登记册将仿照现有的ABMTR/IBMTR登记册的模式。目标2将鼓励和促进制定更多的自愿机构标准（AABB，NMDP和FACT），旨在确保提高干细胞供体的安全性。人们普遍认为，应制定更多的捐助者安全标准。本次专题讨论会将讨论对此类标准的需求，并推动这一进程。AIM 3将在一份全国公认的期刊上发表专题讨论会的摘要。

DESCRIPTION (provided by applicant): This grant is submitted in support of an R-13 application (Grant Support for Conferences and Scientific Meetings) to the NIH for a non-recurring one and one-half day conference entitled: Safeguarding Adult and Pediatric Stem Cell Donors: Basic Science, Clinical and Ethical Issues. The Symposium will be held on Tuesday September 21 (am and pm) and Wednesday September 22, 2004 (am only) and will be located in the Masur Auditorium NIH Clinical Center (Building 10), Bethesda, MD. This one and one-half-day Symposium will be designed to address key issues related to the safety of pediatric and adult, related and unrelated allogeneic donors providing stem cells via bone marrow aspiration, peripheral blood stem cell or cord blood collection. Examples of these issues include the safety and the mechanism of action of G-CSF mobilization, risks of musculoskeletal and neuromuscular damage from bone marrow aspiration, risk of hypocalcemia and central catheter complications in apheresis peripheral blood stem cell donors, and the ethics of exposing related donors (especially pediatric donors) to G-CSF or other mobilizing agents. Speakers will include leaders in the field of adult and pediatric stem cell transplantation, ethicists and transfusion medicine specialists. AIM 1 of the Symposium will be to facilitate development of a National or International Donor Registry database that would follow matched-unrelated as well as related allogeneic donors for years post donation. The Registry would be patterned after the ABMTR/IBMTR registry currently in existence. AIM 2 will be to encourage and facilitate the development of additional voluntary agency Standards (AABB, NMDP and FACT) aimed at ensuring increased stem cell donor safety. There is general consensus that additional donor safety Standards should be developed. This Symposium would address the need for such Standards and stimulate the process. AIM 3 will be to publish a summary of the Symposium in a nationally recognized Journal.